SG11201601823TA - Methods and compositions comprising purified recombinant polypeptides - Google Patents

Methods and compositions comprising purified recombinant polypeptides

Info

Publication number
SG11201601823TA
SG11201601823TA SG11201601823TA SG11201601823TA SG11201601823TA SG 11201601823T A SG11201601823T A SG 11201601823TA SG 11201601823T A SG11201601823T A SG 11201601823TA SG 11201601823T A SG11201601823T A SG 11201601823TA SG 11201601823T A SG11201601823T A SG 11201601823TA
Authority
SG
Singapore
Prior art keywords
compositions
methods
purified recombinant
recombinant polypeptides
polypeptides
Prior art date
Application number
SG11201601823TA
Other languages
English (en)
Inventor
X Christopher Yu
Fischer Saloumeh Kadkhodayan
Susan C Fisher
John Lowe
Atia Naim
Ailen M Sanchez
Christopher A Teske
Martin Vanderlaan
Annamarie Amurao
Jayme Franklin
Corazon Victa
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of SG11201601823TA publication Critical patent/SG11201601823TA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39516—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum from serum, plasma
    • A61K39/39525—Purification
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—DNA viruses
    • C07K16/085—Orthoherpesviridae (F), e.g. pseudorabies virus or Epstein-Barr virus
    • C07K16/088—Varicella-zoster virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—DNA viruses
    • C07K16/085—Orthoherpesviridae (F), e.g. pseudorabies virus or Epstein-Barr virus
    • C07K16/089—Cytomegalovirus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Analytical Chemistry (AREA)
  • Virology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG11201601823TA 2013-09-13 2014-09-12 Methods and compositions comprising purified recombinant polypeptides SG11201601823TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361877517P 2013-09-13 2013-09-13
PCT/US2014/055387 WO2015038888A1 (fr) 2013-09-13 2014-09-12 Procédés et compositions comprenant des polypeptides recombinants purifiés

Publications (1)

Publication Number Publication Date
SG11201601823TA true SG11201601823TA (en) 2016-04-28

Family

ID=52666315

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201802525QA SG10201802525QA (en) 2013-09-13 2014-09-12 Methods and compositions comprising purified recombinant polypeptides
SG11201601823TA SG11201601823TA (en) 2013-09-13 2014-09-12 Methods and compositions comprising purified recombinant polypeptides

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10201802525QA SG10201802525QA (en) 2013-09-13 2014-09-12 Methods and compositions comprising purified recombinant polypeptides

Country Status (18)

Country Link
US (8) US9920120B2 (fr)
EP (3) EP3683232A1 (fr)
JP (4) JP6751344B2 (fr)
KR (2) KR102571391B1 (fr)
CN (2) CN120904322A (fr)
AR (3) AR097651A1 (fr)
AU (2) AU2014318615B2 (fr)
BR (1) BR112016004413A2 (fr)
CA (2) CA3184564A1 (fr)
HK (1) HK1225988A1 (fr)
IL (2) IL244149B2 (fr)
MX (3) MX382393B (fr)
MY (2) MY176026A (fr)
NZ (3) NZ756749A (fr)
RU (1) RU2671481C2 (fr)
SG (2) SG10201802525QA (fr)
WO (1) WO2015038888A1 (fr)
ZA (4) ZA201601965B (fr)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6592426B2 (ja) 2013-03-15 2019-10-16 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． 無塩条件下で疎水性相互作用クロマトグラフィーを使用するタンパク質精製
EP2969098B1 (fr) 2013-03-15 2019-10-30 Glaxosmithkline Intellectual Property (No. 2) Limited Procédés de purification d'anticorps
CN120904322A (zh) * 2013-09-13 2025-11-07 豪夫迈·罗氏有限公司 包含纯化的重组多肽的方法和组合物
AR102198A1 (es) 2014-10-09 2017-02-08 Regeneron Pharma Proceso para reducir partículas subvisibles en una formulación farmacéutica
TW201702380A (zh) 2015-02-27 2017-01-16 再生元醫藥公司 宿主細胞蛋白質修飾
KR20180048731A (ko) * 2015-08-20 2018-05-10 제넨테크, 인크. 재조합 폴리펩티드를 제조하기 위한 fkpa의 정제 및 그의 용도
HRP20211737T1 (hr) 2015-08-21 2022-02-18 F. Hoffmann - La Roche Ag Postupak za smanjenje proteina stanice domaćina u afinitetnoj kromatografiji
SI3337812T1 (sl) * 2015-08-21 2021-08-31 F. Hoffmann-La Roche Ag Postopek za zmanjševanje beljakovin gostiteljske celice v afinitetni kromatografiji
BR112018071107A2 (pt) * 2016-04-14 2019-04-16 Lonza Ltd composições e métodos para a detecção de proteínas da célula hospedeira
JP6871948B2 (ja) 2016-04-27 2021-05-19 アッヴィ・インコーポレイテッド 抗ｉｌ−１３抗体を使用する、ｉｌ−１３活性が有害である疾患の治療方法
CA3031028C (fr) * 2016-07-25 2024-02-13 Lu Wang Tampon de lavage pour chromatographie par affinite
US11020686B2 (en) 2016-08-16 2021-06-01 Regeneron Pharmaceuticals, Inc. Methods for quantitating individual antibodies from a mixture
RU2759909C2 (ru) 2016-09-07 2021-11-18 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Способы очистки антител
KR20190057083A (ko) * 2016-10-06 2019-05-27 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 공정 불순물에 대한 결합이 감소된 항체
JP7102401B2 (ja) 2016-10-25 2022-07-19 リジェネロン・ファーマシューティカルズ・インコーポレイテッド クロマトグラフィーデータ解析のための方法およびシステム
CR20190291A (es) 2016-12-23 2019-11-05 Serum Institute Of India Pvt Ltd Métodos mejorados para estimular la productividad de anticuerpos en el cultivo de células de mamiferos y reducir la agregación durante los procesos de formulación post-tratamiento (downstream) y formulaciones de anticuerpos estables obtenidas a partir de los mismos
CA3073935A1 (fr) 2017-09-19 2019-03-28 Regeneron Pharmaceuticals, Inc. Procedes de reduction de la formation de particules et compositions formees par ceux-ci
TW202003555A (zh) * 2018-03-07 2020-01-16 英商葛蘭素史克智慧財產發展有限公司 用於純化重組多肽之方法
TWI853823B (zh) 2018-07-02 2024-09-01 美商里珍納龍藥品有限公司 自混合物製備多肽之系統及方法
EP3826743A4 (fr) * 2018-07-25 2022-09-14 Merck Sharp & Dohme Corp. Procédés de séparation de lipases de cellules hôtes à partir d'une protéine de production dans des procédés chromatographiques
WO2020153390A1 (fr) 2019-01-23 2020-07-30 第一三共株式会社 Procédé de purification d'anticorps comprenant une étape utilisant un matériau de carbone activé
WO2020157749A1 (fr) * 2019-01-29 2020-08-06 Bnai Zion Medical Center Anticorps anti il-17 utilisé dans le traitement de l'urticaire spontanée chronique
EA202192422A1 (ru) 2019-03-05 2021-12-09 Ридженерон Фармасьютикалз, Инк. Человеческий сывороточный альбумин в составах
AU2020257220A1 (en) * 2019-04-17 2021-11-11 Regeneron Pharmaceuticals, Inc. Identification of host cell proteins
EP3973291A1 (fr) * 2019-05-21 2022-03-30 Regeneron Pharmaceuticals, Inc. Procédés d'identification et de quantification de protéine de cellule hôte
US20220314142A1 (en) * 2019-07-01 2022-10-06 Pfizer Inc. Improvements to wash solutions for protein a chromatography in an antibody purification process
CA3156649A1 (fr) * 2019-10-04 2021-04-08 Merck Patent Gmbh Purification de proteines et inactivation virale
EP4096802A4 (fr) * 2020-01-29 2024-07-03 Merck Sharp & Dohme LLC Procédés de séparation de lipases de cellules hôtes d'une production d'anticorps anti-lag3
JP2022023813A (ja) * 2020-07-27 2022-02-08 ファイザー・インク 組換え生産されたｒｓｖタンパク質の精製方法における陰イオン交換クロマトグラフィー用洗浄溶液の改良
US20230054648A1 (en) * 2021-05-03 2023-02-23 Agilent Technologies, Inc. Chimeric immunogens and methods for making polyclonal antibodies against specific epitopes
AU2023265659A1 (en) * 2022-05-02 2024-12-12 Regeneron Pharmaceuticals, Inc. Methods for reducing lipase activity
EP4540284A2 (fr) 2022-06-17 2025-04-23 Apogee Therapeutics, Inc. Anticorps se liant à l'interleukine 13 et méthodes d'utilisation
CN120641127A (zh) * 2022-12-19 2025-09-12 伊莱利利公司 减少蛋白纯化中污染物的方法
AU2024334289A1 (en) 2023-08-25 2026-04-09 Proteologix Us Inc. Anti-il-13 multispecific antibody constructs and uses thereof
CN117169518B (zh) * 2023-11-03 2024-01-19 赛德特(北京)生物工程有限公司 T淋巴细胞制剂中的cd3抗体残留物的检测方法和试剂盒
TW202535949A (zh) 2023-12-20 2025-09-16 美商必治妥美雅史谷比公司 靶向IL-18受體β(IL-18RB)之抗體及相關方法

Family Cites Families (187)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2046920B1 (fr) 1969-06-19 1974-05-03 Citizen Watch Co Ltd
US3691016A (en) 1970-04-17 1972-09-12 Monsanto Co Process for the preparation of insoluble enzymes
US3940475A (en) 1970-06-11 1976-02-24 Biological Developments, Inc. Radioimmune method of assaying quantitatively for a hapten
CA1023287A (fr) 1972-12-08 1977-12-27 Boehringer Mannheim G.M.B.H. Procede de fixation d'une proteine sur un substrat
US4195128A (en) 1976-05-03 1980-03-25 Bayer Aktiengesellschaft Polymeric carrier bound ligands
US4330440A (en) 1977-02-08 1982-05-18 Development Finance Corporation Of New Zealand Activated matrix and method of activation
CA1093991A (fr) 1977-02-17 1981-01-20 Hideo Hirohara Traduction non-disponible
US4229537A (en) 1978-02-09 1980-10-21 New York University Preparation of trichloro-s-triazine activated supports for coupling ligands
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE3422247A1 (de) 1984-06-15 1985-12-19 Pfeifer & Langen, 5000 Köln Gluco-oligosaccharid-gemisch und verfahren zu seiner herstellung
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
WO1989004838A1 (fr) 1987-11-25 1989-06-01 Immunex Corporation Recepteurs d'interleukine-1
US5359037A (en) 1988-09-12 1994-10-25 Yeda Research And Development Co. Ltd. Antibodies to TNF binding protein I
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
AU643427B2 (en) 1988-10-31 1993-11-18 Immunex Corporation Interleukin-4 receptors
US4847745A (en) 1988-11-16 1989-07-11 Sundstrand Corp. Three phase inverter power supply with balancing transformer
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5011778A (en) 1989-05-23 1991-04-30 Otsuka Pharmaceutical Co., Ltd. Monoclonal antibodies directed to IL-1 activated endothelial cells and medicaments employing the monoclonal antibodies
EP0402226A1 (fr) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Vecteurs de transformation de la levure yarrowia
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
ATE136906T1 (de) 1989-12-20 1996-05-15 Schering Corp Antikörperantagonisten gegen humanes interleukin- 4
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
EP0506574B1 (fr) 1991-03-29 1995-11-29 Sanofi Protéine à activité de type cytokine, ADN recombinant codant pour cette protéine, cellules et microorganismes transformés
MX9204374A (es) 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
US6329509B1 (en) 1991-08-14 2001-12-11 Genentech, Inc. Anti-IgE antibodies
US5965709A (en) 1991-08-14 1999-10-12 Genentech, Inc. IgE antagonists
US5994514A (en) 1991-08-14 1999-11-30 Genentech, Inc. Immunoglobulin variants
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
FI941572A7 (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä
ATE207080T1 (de) 1991-11-25 2001-11-15 Enzon Inc Multivalente antigen-bindende proteine
CA2372813A1 (fr) 1992-02-06 1993-08-19 L.L. Houston Proteine fixatrice biosynthetique pour marqueur du cancer
WO1993015766A1 (fr) 1992-02-10 1993-08-19 Seragen, Inc. Desensibilisation concernant des allergenes specifiques
WO1993016177A1 (fr) 1992-02-11 1993-08-19 Cell Genesys, Inc. Homogeneisation de ciblages de genes
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
CA2096289A1 (fr) 1992-05-15 1993-11-16 Wouter Musters Clonage et expression de l'adn encodant une forme de polypeptide a activite rhamnogalacturonase, intervenant dans le murissement
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
WO1994004680A1 (fr) 1992-08-21 1994-03-03 Schering Corporation Interleukine-13 humaine
US5596072A (en) 1992-08-21 1997-01-21 Schering Corporation Method of refolding human IL-13
DK0752248T3 (da) 1992-11-13 2000-11-13 Idec Pharma Corp Terapeutisk anvendelse af kimæriske og radioaktivt mærkede antistoffer mod humant B-lymfocytbegrænset differentieringsantig
EP0604693A1 (fr) 1992-12-29 1994-07-06 Schering-Plough Anticorps monoclonaux contre le récepteur de l'interleukine-4 humain et hydridomes les produisant
DE69415669T2 (de) 1993-05-17 1999-07-01 Genentech, Inc., South San Francisco, Calif. Sialidase defiziente zellen
ES2143553T3 (es) 1993-09-02 2000-05-16 Dartmouth College Anticuerpos anti-gp39 y sus utilizaciones.
EP0659766A1 (fr) 1993-11-23 1995-06-28 Schering-Plough Anticorps monoclonaux humains contre des cytokines humains et méthode de fabrication de tels anticorps
US5429746A (en) 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
US5534615A (en) 1994-04-25 1996-07-09 Genentech, Inc. Cardiac hypertrophy factor and uses therefor
GB9415379D0 (en) 1994-07-29 1994-09-21 Smithkline Beecham Plc Novel compounds
US5705154A (en) 1995-03-08 1998-01-06 Schering Corporation Humanized monoclonal antibodies against human interleukin-4
US6037453A (en) 1995-03-15 2000-03-14 Genentech, Inc. Immunoglobulin variants
US6518061B1 (en) 1995-03-15 2003-02-11 The United States Of America As Represented By The Department Of Health And Human Services IL-13 receptor specific chimeric proteins and uses thereof
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US6911530B1 (en) 1995-10-23 2005-06-28 Amrad Operations, Pty., Ltd. Haemopoietin receptor and genetic sequences encoding same
JP4224135B2 (ja) 1995-10-23 2009-02-12 ズィナイス セラピューティックス ピーティーワイ．エルティーディー． 新規なヘモポエチン受容体およびそれをコードする遺伝子配列
FR2742156A1 (fr) 1995-12-06 1997-06-13 Sanofi Sa Polypeptide recepteur de l'il-13
MX336813B (es) 1996-02-09 2016-02-02 Abbvie Biotechnology Ltd Anticuerpos humanos que ligan el tnfa humano.
US7078494B1 (en) 1996-03-01 2006-07-18 Genetics Institute, Llc Antibodies to human IL-13bc and methods of their use in inhibiting IL-13 binding
US5710023A (en) 1996-03-01 1998-01-20 Genetics Institute, Inc. IL-13 cytokine receptor chain
US6664227B1 (en) 1996-03-01 2003-12-16 Genetics Institute, Llc Treatment of fibrosis by antagonism of IL-13 and IL-13 receptor chains
WO1997047742A1 (fr) 1996-06-12 1997-12-18 Smithkline Beecham Corporation Recepteur hr-1
WO1998010638A1 (fr) 1996-09-10 1998-03-19 Amrad Operations Pty. Ltd. Molecules d'interet therapeutique
DE69738075T2 (de) 1996-11-27 2008-05-21 Genentech, Inc., South San Francisco Affinitätsreinigung von polypeptiden an einer protein a-matrix
US6743604B1 (en) 1996-12-13 2004-06-01 Smithkline Beecham Corporation Substances and their uses
GB9625899D0 (en) 1996-12-13 1997-01-29 Glaxo Group Ltd Substances and their uses
CN1247472A (zh) 1997-01-10 2000-03-15 拜奥根有限公司 用抗cd40l化合物治疗狼疮性肾炎
WO1998031394A2 (fr) 1997-01-22 1998-07-23 Board Of Regents, The University Of Texas System Methodes et compositions de thromboplastine tissulaire pour le traitement de la coagulation et des tumeurs
US6576232B1 (en) 1998-04-03 2003-06-10 The Penn State Research Foundation IL13 mutants
US6482403B1 (en) 1998-05-29 2002-11-19 Heska Corporation Caniney IL-13 immunoregulatory proteins and uses thereof
US6299875B1 (en) 1998-06-04 2001-10-09 Panacea Pharmaceuticals, Llc Methods to block IGE binding to cell surface receptors of mast cells
GB9820014D0 (en) 1998-09-14 1998-11-04 Cancer Res Campaign Tech Receptor antagonists and uses thereof
US7083950B2 (en) 1998-09-25 2006-08-01 Regeneron Pharmaceuticals, Inc. High affinity fusion proteins and therapeutic and diagnostic methods for use
DE19848026A1 (de) 1998-10-17 2000-04-20 Bayer Ag Verfahren zur Herstellung von Bis(4-hydroxyaryl)alkanen
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
MXPA01006006A (es) 1998-12-14 2004-08-12 Genetics Inst Cadena receptora de citocina.
US7553487B2 (en) 1998-12-14 2009-06-30 Genetics Institute, Llc Method and compositions for treating asthma
WO2000044407A2 (fr) 1999-02-01 2000-08-03 Amgen Canada Materiaux et methodes d'inhibition de l'accroissement cellulaire d'hodgkin et de reed sternberg
EP1263785A2 (fr) 1999-11-11 2002-12-11 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Modulation de l'activite de il-13 au moyen de molecules il-13 qui sont des antagonistes ou des agonistes de il-13
US20100041039A1 (en) 2000-01-15 2010-02-18 Synageva Biopharma Corp. Analysis of nucleic acid obtained from nucleated red blood cells
DE1257584T1 (de) 2000-02-24 2003-05-28 Lilly Co Eli Humanisierte antikörper, die amyloid beta peptid demarkieren
ATE402192T1 (de) 2000-03-03 2008-08-15 Kyowa Hakko Kogyo Kk Anti-ccr4 antikörper und fragmente davon
CN1323812A (zh) 2000-05-16 2001-11-28 上海博德基因开发有限公司 一种新的多肽——人白细胞介素－13(il－13)受体11和编码这种多肽的多核苷酸
EP1333850B1 (fr) 2000-10-20 2008-08-20 Genetics Institute, Inc. Utilisation des inhibiteurs de l'il-13 pour le traitement de tumeurs
AU1091802A (en) 2000-10-20 2002-04-29 Chugai Pharmaceutical Co Ltd Degraded agonist antibody
US7919467B2 (en) 2000-12-04 2011-04-05 Immunotope, Inc. Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
US8372954B2 (en) 2000-12-22 2013-02-12 National Research Council Of Canada Phage display libraries of human VH fragments
JP2005518336A (ja) 2001-06-26 2005-06-23 イムクローン システムズ インコーポレイティド Ｖｅｇｆ受容体に結合する二重特異性抗体
US20030023555A1 (en) 2001-07-26 2003-01-30 Cashworks, Inc. Method and system for providing financial services
CA2458627C (fr) 2001-08-31 2013-09-10 Kyowa Kirin Co., Ltd. Anticorps greffes cdr humains et fragments de ces anticorps
US6908963B2 (en) 2001-10-09 2005-06-21 Nektar Therapeutics Al, Corporation Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
CA2464695A1 (fr) 2001-10-26 2003-05-01 Centocor, Inc. Proteines muteines il-13, anticorps, compositions, procedes et utilisations
AU2002363382B2 (en) 2001-11-07 2007-07-19 Cytos Biotechnology Ag Antigen arrays presenting IL-5, IL-3 or eotaxin for treatment of allergic eosinophilic diseases
CA2473144C (fr) 2002-02-05 2013-05-28 Genentech, Inc. Purification de proteines
AU2003223497A1 (en) 2002-04-05 2003-10-27 Centocor, Inc. Asthma-related anti-il-13 immunoglobulin derived proteins, compositions, methods and uses
US20040060102A1 (en) 2002-04-10 2004-04-01 Interspiro, Inc. Garments for biological, chemical and fire protection
WO2003102132A2 (fr) 2002-04-26 2003-12-11 Genetech, Inc. Purification de proteines basee sur la non affinite
ES2365210T3 (es) 2002-06-14 2011-09-26 Government Of The United States Of America, As Represented By The Secretary, Department Of Health Procedimientos de tratamiento y prevención de colitis en la que se implican la il-13 y los linfocitos t citolíticos naturales.
WO2004019975A2 (fr) 2002-08-30 2004-03-11 Glaxo Group Limited Vaccin
JP2006503017A (ja) 2002-08-30 2006-01-26 グラクソ　グループ　リミテッド Ｉｌ−１３要素及びｔ細胞エピトープを含む免疫原組成物並びにその治療上の使用
DE10303664A1 (de) 2003-01-23 2004-08-12 Nemod Immuntherapie Ag Erkennungsmoleküle zur Behandlung und Detektion von Tumoren
ATE468886T1 (de) 2003-02-10 2010-06-15 Applied Molecular Evolution Abeta-bindende moleküle
US7157276B2 (en) 2003-06-20 2007-01-02 Biogen Idec Inc. Use of depth filtration in series with continuous centrifugation to clarify mammalian cell cultures
DE602004017726D1 (de) 2003-06-30 2008-12-24 Domantis Ltd Pegylierte Single-domain-antikörper (dAb)
GB0407315D0 (en) 2003-07-15 2004-05-05 Cambridge Antibody Tech Human antibody molecules
PL3718564T3 (pl) 2003-12-23 2024-03-18 Genentech, Inc. Nowe przeciwciała anty-IL 13 i ich zastosowania
SI2311873T1 (sl) 2004-01-07 2018-12-31 Novartis Vaccines And Diagnostics, Inc. M-CSF-specifična monoklonska protitelesa in njihova uporaba
WO2005071410A1 (fr) 2004-01-13 2005-08-04 Tanox, Inc. Detection et quantification de proteines de cellules hotes dans des produits proteiques recombinants
US20050226883A1 (en) 2004-02-06 2005-10-13 Paul Averback Humanized antibody
SI1720909T1 (sl) 2004-02-23 2012-01-31 Lilly Co Eli Anti-abeta protitelo
KR20070008645A (ko) 2004-05-04 2007-01-17 노보 노르디스크 헬스 케어 악티엔게젤샤프트 폴리펩티드의 ｏ-연결된 단백당형 및 그들의 제조 방법
US20070037966A1 (en) * 2004-05-04 2007-02-15 Novo Nordisk A/S Hydrophobic interaction chromatography purification of factor VII polypeptides
US7501121B2 (en) 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
US20070048785A1 (en) 2004-06-09 2007-03-01 Lin Laura L Anti-IL-13 antibodies and complexes
AR049390A1 (es) 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
TWI307630B (en) 2004-07-01 2009-03-21 Glaxo Group Ltd Immunoglobulins
AU2005299716B2 (en) 2004-10-22 2012-09-06 Amgen Inc. Methods for refolding of recombinant antibodies
WO2006066308A1 (fr) 2004-12-24 2006-06-29 Commonwealth Scientific And Industrial Research Organisation Compositions et procedes pesticides
EP1869065B1 (fr) 2005-03-11 2020-05-06 Wyeth LLC Procede de chromatographie a faible separation
EP1869067A1 (fr) 2005-04-11 2007-12-26 Medarex, Inc. Purification des proteines utilisant la hcic et la chromatographie par echange d'ions
ZA200710330B (en) 2005-06-17 2009-12-30 Wyeth Corp Methods of purifying FC region containing proteins
JP3982545B2 (ja) 2005-09-22 2007-09-26 ダイキン工業株式会社 空気調和装置
AU2006296399B2 (en) * 2005-09-30 2011-01-20 Medimmune Limited Interleukin-13 antibody composition
WO2007045477A2 (fr) 2005-10-21 2007-04-26 Novartis Ag Molecules organiques
HRP20140240T4 (hr) 2005-11-30 2017-02-24 Abbvie Inc. Monoklonalna antitijela protiv amiloidnih beta proteina i njihova upotreba
US7667557B2 (en) 2005-12-06 2010-02-23 Tdk Corporation Thin-film bandpass filter using inductor-capacitor resonators
MY155286A (en) 2005-12-12 2015-09-30 Hoffmann La Roche Antibodies against amyloid beta 4 with glycosylated in the variable region
EP1959996A2 (fr) 2005-12-12 2008-08-27 AC Immune S.A. Anticorps monoclonal
ATE550353T1 (de) 2005-12-30 2012-04-15 Merck Patent Gmbh Die bindung von mit il-6ralpha komplexiertem il-6 an gp130 verhindernde anti-il-6-antikörper
US7563875B2 (en) 2006-03-20 2009-07-21 The United States of America as represented by the Sercretary of the Army Recombinant chimeric human anti-botulinum antibodies
CN102887955A (zh) * 2006-04-05 2013-01-23 艾博特生物技术有限公司 抗体纯化
JP2009534035A (ja) 2006-04-21 2009-09-24 ワイス 細胞系のハイスループットスクリーニング方法
EP2046833B9 (fr) 2006-07-14 2014-02-19 AC Immune S.A. Anticorps humanisé contre l'amyloid beta
CL2007002567A1 (es) 2006-09-08 2008-02-01 Amgen Inc Proteinas aisladas de enlace a activina a humana.
EP2057274B1 (fr) 2006-09-21 2013-12-11 DSM IP Assets B.V. Phospholipases, acides nucléiques codant pour elles et leurs méthodes d'obtention et d'utilisation
SI2074145T1 (sl) 2006-10-02 2017-12-29 Ac Immune S.A. Humanizirano protitelo proti amiloid beta
DK2457929T3 (en) 2006-10-04 2016-09-05 Genentech Inc Elisa vegf
US8383350B1 (en) 2006-12-20 2013-02-26 Merck Sharp & Dohme Corp. Assay for detection of IL-10 antibodies
CA2674608A1 (fr) 2007-01-09 2008-07-17 Wyeth Preparations d'anticorps ant-il-13 et leurs utilisations
WO2008140455A1 (fr) 2007-05-15 2008-11-20 Tanox, Inc. Traitement de la fibrose induite par radiation et chimiothérapie à l'aide de nouveaux anticorps monoclonaux anti-il-13
ES2529174T3 (es) 2007-06-12 2015-02-17 Ac Immune S.A. Anticuerpos humanizados para amiloide beta
NZ581835A (en) 2007-06-12 2012-09-28 Ac Immune Sa Monoclonal anti beta amyloid antibody
US9433922B2 (en) 2007-08-14 2016-09-06 Emd Millipore Corporation Media for membrane ion exchange chromatography based on polymeric primary amines, sorption device containing that media, and chromatography scheme and purification method using the same
BRPI0818623A2 (pt) 2007-10-05 2017-05-23 Ac Immune Sa composição farmacêutica, e, métodos para reduzir a carga da placa na camada de célula de gânglio retinal de um animal, para reduzir a quantidade de placas na camada de célula de gânglio retinal de um animal, para diminuir a quantidade total de amilóide-beta solúvel na camada de célula de gânglio retinal de um animal, para prevenir, tratar e/ou aliviar os efeitos de uma doença ocular associada com anormalidades patológicas/mudanças no tecido do sistema visual, para monitorar doença ocular residual mínima associada com anormalidades patológicas/mudanças nos tecidos do sistema visual, para predizer responsividade de um paciente, e para reter ou diminuir a pressão ocular nos olhos de um animal
US20100297013A1 (en) 2007-10-05 2010-11-25 Andrea Pfeifer Humanized antibody
AU2008311367B2 (en) 2007-10-05 2014-11-13 Ac Immune S.A. Use of anti-amyloid beta antibody in ocular diseases
WO2009058769A1 (fr) * 2007-10-30 2009-05-07 Schering Corporation Purification d'anticorps contenant des variants hydrophobes
BRPI0906261A2 (pt) 2008-03-31 2015-07-07 Genentech Inc "métodos de diagnóstico de um subtipo de asma em uma amostra de paciente, usos de um agente terapêutico e kits de diagnóstico de um subtipo de asma em uma amostra de paciente"
US8344115B2 (en) 2008-04-21 2013-01-01 Chan-Sui Pang, legal representative Immunoassay for specific determination of S-adenosylmethionine and analogs thereof in biological samples
RU2474588C2 (ru) 2008-05-05 2013-02-10 Новиммун Са Перекрестно-реактивные антитела анти-il-17a/il-17f и способы их применения
BRPI0911926A2 (pt) 2008-08-05 2020-08-18 Toray Industries, Inc composições farmacêuticas, anticorpos e usos de um anticorpo ou um fragmento do mesmo.
US8790642B2 (en) * 2008-08-29 2014-07-29 Genentech, Inc. Cross-reactive and bispecific anti-IL-17A/F antibodies
GB0818674D0 (en) 2008-10-10 2008-11-19 Univ Bath Materials and methods for resolving polyhydric species by electrophoresis
NZ592095A (en) 2008-10-20 2013-01-25 Abbott Lab Isolation and purification of il-12 and tnf-alpha antibodies using protein a affinity chromatography
BRPI0920572A8 (pt) 2008-10-20 2015-10-27 Abbott Lab Inativação viral durante a purificação dos anticorpos
MX2011004199A (es) 2008-10-20 2011-05-24 Abbott Lab Anticuerpos que unen a il-18 y metodos para purificar los mismos.
MX2011004198A (es) 2008-10-20 2011-05-24 Abbott Lab Anticerpos que unen a il-12 y metodos para purificar los mismos.
CN101979404B (zh) 2008-12-09 2015-01-14 厦门大学 H5亚型禽流感病毒保守中和表位模拟肽及其用途
FR2944448B1 (fr) 2008-12-23 2012-01-13 Adocia Composition pharmaceutique stable comprenant au moins un anticorps monodonal et au moins un polysacharide amphiphile comprenant des substituants derives d'alcools hydrofobes ou d'amines hydrophobes.
WO2011010940A1 (fr) 2009-07-19 2011-01-27 Serguei Zavtrak Générateur d’énergie électrique solaire
EP3309168A1 (fr) 2009-08-06 2018-04-18 F. Hoffmann-La Roche AG Procédé pour améliorer l'élimination de virus dans la purification de protéines
KR101790802B1 (ko) 2009-09-03 2017-10-27 머크 샤프 앤드 돔 코포레이션 항-ｇｉｔｒ 항체
UA109884C2 (uk) 2009-10-16 2015-10-26 Поліпептид, що має активність ферменту фосфатидилінозитол-специфічної фосфоліпази с, нуклеїнова кислота, що його кодує, та спосіб його виробництва і застосування
ES2813398T3 (es) * 2009-10-20 2021-03-23 Abbvie Inc Aislamiento y purificación de anticuerpos anti-IL-13 usando cromatografía de afinidad a Proteína A
DK2530091T3 (en) 2010-01-29 2018-05-28 Chugai Pharmaceutical Co Ltd ANTI-DLL3 ANTIBODY
PH12012501751A1 (en) 2010-03-04 2012-11-12 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
EP2542256B1 (fr) 2010-03-04 2019-05-22 MacroGenics, Inc. Anticorps réagissant avec b7-h3, fragments immunologiquement actifs associés et utilisations associées
PT2569013T (pt) 2010-05-14 2017-02-08 Univ Leland Stanford Junior Anticorpos monoclonais humanizados e quiméricos para cd47
EA201500220A1 (ru) 2010-05-17 2015-10-30 Ливтех, Инк. Антитело против trop-2 человека, обладающее противоопухолевой активностью in vivo
KR101976853B1 (ko) 2010-05-25 2019-05-09 제넨테크, 인크. 폴리펩티드의 정제 방법
AR082194A1 (es) 2010-07-06 2012-11-21 Aveo Pharmaceuticals Inc Anticuerpos anti-ron
EP2598882B1 (fr) 2010-07-30 2017-07-26 AC Immune S.A. Anticorps humanisés sûrs et fonctionnels pour utilisation dans le traitement de l'amyloïdose
WO2012047732A2 (fr) 2010-09-29 2012-04-12 Genentech, Inc. Compositions d'anticorps et procédés d'utilisation
CA2818173C (fr) * 2010-11-30 2022-05-03 Genentech, Inc. Anticorps anti-recepteur de la barriere hemato-encephalique a faible affinite et leurs utilisations
RU2578468C2 (ru) 2010-12-16 2016-03-27 Дженентек, Инк. Способы диагностики и лечения, связанные с ингибированием th2
JP6072771B2 (ja) 2011-04-20 2017-02-01 メディミューン，エルエルシー Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子
US9096648B2 (en) * 2011-08-19 2015-08-04 Emd Millipore Corporation Methods of reducing level of one or more impurities in a sample during protein purification
ES2936387T3 (es) * 2011-10-31 2023-03-16 Hoffmann La Roche Formulaciones de anticuerpos anti-il13
EP2773439A4 (fr) * 2011-10-31 2015-07-01 Merck Sharp & Dohme Procédé de chromatographie permettant de décomposer des agrégats d'anticorps hétérogènes
SG11201402485UA (en) * 2011-11-21 2014-06-27 Genentech Inc Purification of anti-c-met antibodies
JP6092892B2 (ja) 2011-12-15 2017-03-08 プレステージ バイオファーマ プライベート リミテッド 抗体の精製方法
WO2013120497A1 (fr) * 2012-02-15 2013-08-22 Curevac Gmbh Acide nucléique comprenant ou codant pour une tige-boucle d'histone et une séquence poly(a) ou un signal de polyadénylation pour l'augmentation de l'expression d'une protéine thérapeutique codée
HK1204926A1 (en) 2012-02-29 2015-12-11 吉联亚生物科技有限公司 Antibodies to matrix metalloproteinase 9
WO2013176754A1 (fr) 2012-05-24 2013-11-28 Abbvie Inc. Nouvelle purification d'anticorps au moyen de chromatographie à interaction hydrophobe
RU2016107435A (ru) * 2013-09-13 2017-10-18 Дженентек, Инк. Композиции и способы обнаружения и количественного определения белка клеток-хозяев в клеточных линиях и рекомбинантные полипептидные продукты
CN120904322A (zh) * 2013-09-13 2025-11-07 豪夫迈·罗氏有限公司 包含纯化的重组多肽的方法和组合物
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography

Also Published As

Publication number Publication date
EP3043820A4 (fr) 2017-07-12
RU2016108828A (ru) 2017-10-18
ZA201801849B (en) 2021-07-28
CA2921999A1 (fr) 2015-03-19
CN105722532A (zh) 2016-06-29
CA2921999C (fr) 2023-03-21
RU2016108828A3 (fr) 2018-05-29
US12312399B2 (en) 2025-05-27
HK1225988A1 (zh) 2017-09-22
US20250250333A1 (en) 2025-08-07
US10597446B2 (en) 2020-03-24
IL244149A0 (en) 2016-04-21
JP6982027B2 (ja) 2021-12-17
JP2019178139A (ja) 2019-10-17
MX2021005364A (es) 2021-06-30
US10494429B2 (en) 2019-12-03
IL320195A (en) 2025-06-01
RU2671481C2 (ru) 2018-10-31
US11667706B2 (en) 2023-06-06
MY176026A (en) 2020-07-22
US20160319012A1 (en) 2016-11-03
AU2014318615B2 (en) 2020-03-12
ZA202201361B (en) 2023-11-29
KR102571391B1 (ko) 2023-08-29
WO2015038888A9 (fr) 2016-03-17
CA3184564A1 (fr) 2015-03-19
MX382393B (es) 2025-03-13
EP3683232A1 (fr) 2020-07-22
AU2020200502B9 (en) 2022-03-24
IL244149B2 (en) 2025-09-01
AU2020200502A1 (en) 2020-02-13
JP2016539176A (ja) 2016-12-15
JP2022036971A (ja) 2022-03-08
JP2024059617A (ja) 2024-05-01
KR102373930B1 (ko) 2022-03-11
MX2021005358A (es) 2021-06-30
US20180291095A1 (en) 2018-10-11
US10597447B2 (en) 2020-03-24
AU2014318615A1 (en) 2016-04-21
SG10201802525QA (en) 2018-04-27
US9920120B2 (en) 2018-03-20
US20180291094A1 (en) 2018-10-11
EP3043820A1 (fr) 2016-07-20
ZA202101142B (en) 2022-09-28
MX2016003202A (es) 2016-06-07
US20230250165A1 (en) 2023-08-10
AU2020200502B2 (en) 2022-03-10
EP4331605A2 (fr) 2024-03-06
IL244149B1 (en) 2025-05-01
US20180273615A1 (en) 2018-09-27
JP7489953B2 (ja) 2024-05-24
BR112016004413A2 (pt) 2017-10-17
AR118560A2 (es) 2021-10-20
US20180312585A1 (en) 2018-11-01
AU2014318615A9 (en) 2016-06-16
JP6751344B2 (ja) 2020-09-02
CN120904322A (zh) 2025-11-07
KR20160052724A (ko) 2016-05-12
KR20220034930A (ko) 2022-03-18
EP4331605A3 (fr) 2024-05-22
NZ718144A (en) 2022-05-27
WO2015038888A1 (fr) 2015-03-19
US10822404B2 (en) 2020-11-03
AR097651A1 (es) 2016-04-06
ZA201601965B (en) 2018-11-28
MY193481A (en) 2022-10-17
NZ756749A (en) 2022-05-27
US20210115126A1 (en) 2021-04-22
AR133787A2 (es) 2025-11-05
NZ756750A (en) 2022-05-27

Similar Documents

Publication Publication Date Title
ZA202101142B (en) Methods and compositions comprising purified recombinant polypeptides
IL320900A (en) Heterodimer proteins
IL276106A (en) Garp-binding proteins and their uses
ZA201505966B (en) Peptides and compositions
PT3058936T (pt) Composição peptídica e respetivos usos
EP2989240A4 (fr) Compositions d'interleukine-10 et leurs utilisations
IL244810A0 (en) Stabilized polypeptides and their uses
GB201321693D0 (en) Composition and uses thereof
HUE047933T2 (hu) Faktor VIII polipeptid készítmények
SG11201508167PA (en) Therapeutic compositions and uses thereof
SG10201707600XA (en) Factor ix polypeptide formulations
IL276126B (en) Preparations containing l-4-chloroquinonerine and their uses
IL272609B (en) Recombinant glycoproteins and their uses
GB201304973D0 (en) Recombinant protein
ZA201507684B (en) Recombinant factor viii formulations
IL240639A0 (en) Formulations and methods for increased recombinant production of protein
IL244956B (en) New peptide compositions
GB201300529D0 (en) Recombinant polypeptide
EP3006564A4 (fr) Nouveau peptide et son utilisation
GB201301022D0 (en) Composition and uses thereof
GB201308242D0 (en) Compositions and uses thereof
GB201301640D0 (en) Methods and peptides